Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,018 across all filing types
Latest filing 2019-11-08 Major Shareholding Noti…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
191108 - Notification de transparence comm.de presse Blackrock (2 TD).pdf
Major Shareholding Notification Classification · 98% confidence The document is a formal announcement from UCB SA regarding transparency declarations received from BlackRock, Inc. The content explicitly details changes in shareholding percentages (crossing the 5% threshold downwards and then upwards) based on transactions occurring on specific dates (November 4th and 5th, 2019). This directly relates to notifications about changes in significant share ownership levels, which corresponds to the Major Shareholding Notification category (MRQ). The document structure is a press release format announcing the receipt of these regulatory filings.
2019-11-08 French
191108- Transparantieverklaring persbericht BlackRock (2TD).pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release from UCB NV, dated November 8, 2019, announcing that it has received two notifications from BlackRock, Inc. regarding changes in its shareholding in UCB, specifically crossing and then falling below the 5% threshold on November 4 and November 5, 2019, respectively. This content directly relates to changes in significant share ownership levels by an external entity. This aligns perfectly with the definition for Major Shareholding Notification (MRQ). Although it is presented as a press release, the core subject matter is the notification of shareholding changes.
2019-11-08 Dutch
191018-Transparency notification press release Vanguard.pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "Transparency notification Vanguard Health Care Fund" and explicitly mentions receiving a transparency notification pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings. It details a change in shareholding (crossing downwards the 5% threshold to 0.00%) by an external entity (Vanguard Health Care Fund) regarding UCB shares. This type of filing, reporting changes in significant share ownership that cross regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is presented as a press release, the core content is the mandatory disclosure of a major shareholder change.
2019-10-19 English
191018- Notification de transparence comm.de presse Vanguard.pdf
Major Shareholding Notification Classification · 99% confidence The document is a formal notification titled "Déclaration de transparence Vanguard Health Care Fund" (Transparency Declaration). It explicitly states that it is a notification received by UCB SA concerning a change in shareholding, specifically crossing down the 5% threshold to 0.00% on October 1, 2019, based on the Belgian law of May 2, 2007, regarding the disclosure of major shareholdings. This content directly corresponds to reporting changes in significant share ownership levels, which matches the definition for Major Shareholding Notification (MRQ). Although it is a regulatory filing, MRQ is the most specific category available for this type of disclosure.
2019-10-19 French
191018- Transparantieverklaring persbericht Vanguard.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled "Transparantieverklaring Vanguard Health Care Fund" (Transparency Declaration Vanguard Health Care Fund) and explicitly states it is a notification regarding the crossing of a threshold (5%) related to the disclosure of important shareholdings, referencing the Belgian law of May 2, 2007. It details the change in the number of voting shares held by Vanguard Health Care Fund in UCB NV, dropping below the 5% threshold to 0.00% as of October 1, 2019. This type of mandatory disclosure concerning changes in significant share ownership aligns directly with the definition of Major Shareholding Notification (MRQ). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it pertains to a specific insider/major shareholder transaction disclosure.
2019-10-19 Dutch
Bimekizumab BE VIVID Press Release_FINAL FOR DISTRIBUTION ENG
Regulatory Filings Classification · 95% confidence The document is a press release dated October 17, 2019, announcing positive results from a Phase 3 clinical study (BE VIVID) for a drug candidate (bimekizumab) in treating psoriasis. It contains detailed efficacy data, quotes from management and investigators, and forward-looking statements typical of a corporate announcement regarding clinical trial outcomes. This content is characteristic of an Earnings Release (ER) or a general corporate announcement, but since it focuses purely on clinical trial results and not quarterly financial performance highlights, it fits best under the category of a significant corporate/scientific update. Given the options, it is a high-level announcement of scientific progress, which often accompanies or precedes an Earnings Release, but is not the ER itself. It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Investor Presentation (IP). Since it is a major announcement of positive clinical data, it functions as a key piece of information for investors, similar to an Earnings Release (ER) which announces period results. However, because it is specifically about clinical trial success and not financial performance metrics for a reporting period, it is most closely aligned with a significant corporate update that might be released outside of standard financial reporting cycles. In the absence of a specific 'Clinical Trial Result Announcement' category, and noting that it is a formal announcement of key findings, it is often grouped with Earnings Releases (ER) or Regulatory Filings (RNS). Given the structure and intent (informing the market of a major development), ER is plausible if the company uses this format for all major news, but RNS is the safest fallback for non-standard, yet material, corporate news. Since it is a 'Regulated Information - Inside Information' announcement, it is a formal regulatory disclosure. I will classify it as a Regulatory Filing (RNS) as it is a material, non-financial-period-specific announcement. Revisiting the definitions: ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is about clinical results, not financial results. Therefore, RNS (General regulatory announcements and fallback) is the most appropriate category for this material, non-financial, regulated announcement.
2019-10-17 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.